Aims and scope
The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
BMJ publishes JITC on behalf of the Society for Immunotherapy of Cancer.
|Publication Model||Open access|
|Indexed by||Web of Science Core Collection: Science Citation Index Expanded; MEDLINE, PubMed Central, Science Citation Index Expanded (SCIE), Scopus, DOAJ, Google Scholar|
|Impact Factor||8.728 (2018)|
|Peer Review Model||Single blind; the names of reviewers are hidden from the author|
Journal statistics (2018)
|Mean time from submission to first decision||44 days|
|Time from acceptance to online publication||21 days|
Rights and permissions
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Its mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.